tetano
Editor, Senior Moderator
Virus Evol
. 2021 Feb 16;7(1):veab013.
doi: 10.1093/ve/veab013. eCollection 2021 Jan.
SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
Juliana D Siqueira[SUP] 1 [/SUP], Livia R Goes[SUP] 1 2 [/SUP], Brunna M Alves[SUP] 1 [/SUP], Pedro S de Carvalho[SUP] 1 [/SUP], Claudia Cicala[SUP] 2 [/SUP], James Arthos[SUP] 2 [/SUP], Jo?o P B Viola[SUP] 3 [/SUP], Andr?ia C de Melo[SUP] 4 [/SUP], Marcelo A Soares[SUP] 1 [/SUP]
Affiliations
Abstract
Numerous factors have been identified to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and disease severity. Cancer patients are more prone to clinically evolve to more severe COVID-19 conditions, but the determinants of such a more severe outcome remain largely unknown. We have determined the full-length SARS-CoV-2 genomic sequences of cancer patients and healthcare workers (non-cancer controls) by deep sequencing and investigated the within-host viral population of each infection, quantifying intrahost genetic diversity. Naso- and oropharyngeal SARS-CoV-2[SUP]+[/SUP] swabs from 57 cancer patients and 14 healthcare workers from the Brazilian National Cancer Institute were collected in April to May 2020. Complete genome amplification using ARTIC network V3 multiplex primers was performed followed by next-generation sequencing. Assemblies were conducted in Geneious R11, where consensus sequences were extracted and intrahost single nucleotide variants were identified. Maximum likelihood phylogenetic analysis was performed using PhyMLv.3.0 and lineages were classified using Pangolin and CoV-GLUE. Phylogenetic analysis showed that all but one strain belonged to clade B1.1. Four genetically linked mutations known as the globally dominant SARS-CoV-2 haplotype (C241T, C3037T, C14408T and A23403G) were found in the majority of consensus sequences. SNV signatures of previously characterized Brazilian genomes were also observed in most samples. Another 85 SNVs were found at a lower frequency (1.4%-19.7%) among the consensus sequences. Cancer patients displayed a significantly higher intrahost viral genetic diversity compared to healthcare workers. This difference was independent of SARS-CoV-2 Ct values obtained at the diagnostic tests, which did not differ between the two groups. The most common nucleotide changes of intrahost SNVs in both groups were consistent with APOBEC and ADAR activities. Intrahost genetic diversity in cancer patients was not associated with disease severity, use of corticosteroids, or use of antivirals, characteristics that could influence viral diversity. Moreover, the presence of metastasis, either in general or specifically in the lung, was not associated with intrahost diversity among cancer patients. Cancer patients carried significantly higher numbers of minor variants compared to non-cancer counterparts. Further studies on SARS-CoV-2 diversity in especially vulnerable patients will shed light onto the understanding of the basis of COVID-19 different outcomes in humans.
Keywords: COVID-19; SARS-CoV-2; cancer; full-length genome; single nucleotide variant.
. 2021 Feb 16;7(1):veab013.
doi: 10.1093/ve/veab013. eCollection 2021 Jan.
SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity
Juliana D Siqueira[SUP] 1 [/SUP], Livia R Goes[SUP] 1 2 [/SUP], Brunna M Alves[SUP] 1 [/SUP], Pedro S de Carvalho[SUP] 1 [/SUP], Claudia Cicala[SUP] 2 [/SUP], James Arthos[SUP] 2 [/SUP], Jo?o P B Viola[SUP] 3 [/SUP], Andr?ia C de Melo[SUP] 4 [/SUP], Marcelo A Soares[SUP] 1 [/SUP]
Affiliations
- PMID: 33738124
- PMCID: PMC7928633
- DOI: 10.1093/ve/veab013
Abstract
Numerous factors have been identified to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and disease severity. Cancer patients are more prone to clinically evolve to more severe COVID-19 conditions, but the determinants of such a more severe outcome remain largely unknown. We have determined the full-length SARS-CoV-2 genomic sequences of cancer patients and healthcare workers (non-cancer controls) by deep sequencing and investigated the within-host viral population of each infection, quantifying intrahost genetic diversity. Naso- and oropharyngeal SARS-CoV-2[SUP]+[/SUP] swabs from 57 cancer patients and 14 healthcare workers from the Brazilian National Cancer Institute were collected in April to May 2020. Complete genome amplification using ARTIC network V3 multiplex primers was performed followed by next-generation sequencing. Assemblies were conducted in Geneious R11, where consensus sequences were extracted and intrahost single nucleotide variants were identified. Maximum likelihood phylogenetic analysis was performed using PhyMLv.3.0 and lineages were classified using Pangolin and CoV-GLUE. Phylogenetic analysis showed that all but one strain belonged to clade B1.1. Four genetically linked mutations known as the globally dominant SARS-CoV-2 haplotype (C241T, C3037T, C14408T and A23403G) were found in the majority of consensus sequences. SNV signatures of previously characterized Brazilian genomes were also observed in most samples. Another 85 SNVs were found at a lower frequency (1.4%-19.7%) among the consensus sequences. Cancer patients displayed a significantly higher intrahost viral genetic diversity compared to healthcare workers. This difference was independent of SARS-CoV-2 Ct values obtained at the diagnostic tests, which did not differ between the two groups. The most common nucleotide changes of intrahost SNVs in both groups were consistent with APOBEC and ADAR activities. Intrahost genetic diversity in cancer patients was not associated with disease severity, use of corticosteroids, or use of antivirals, characteristics that could influence viral diversity. Moreover, the presence of metastasis, either in general or specifically in the lung, was not associated with intrahost diversity among cancer patients. Cancer patients carried significantly higher numbers of minor variants compared to non-cancer counterparts. Further studies on SARS-CoV-2 diversity in especially vulnerable patients will shed light onto the understanding of the basis of COVID-19 different outcomes in humans.
Keywords: COVID-19; SARS-CoV-2; cancer; full-length genome; single nucleotide variant.